This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Metabolix, Inc.

Ryan & Maniskas, LLP ( www.rmclasslaw.com/cases/mblx) announces that a class action lawsuit has been filed in United States District Court for the District of Massachusetts on behalf of purchasers of the common stock of Metabolix, Inc. ("Metabolix" or the "Company") (NASDAQ: MBLX) from March 10, 2010 through January 12, 2012, inclusive (the "Class Period").

For more information regarding this class action suit, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at rmaniskas@rmclasslaw.com or visit: www.rmclasslaw.com/cases/mblx.

Metabolix is a bioscience company focused on bringing environmentally friendly solutions to the plastics, chemicals and energy industries. The Company has core capabilities in microbial genetics, fermentation process engineering, chemical engineering, polymer science, plant genetics and botanical science. The Company's largest platform, which it commercialized through Telles, its joint venture with Archer-Daniels-Midland Company ("ADM"), is a large-scale microbial fermentation system for producing a versatile family of polymers known as PHA's which it had branded under the name Mirel. Through Telles, Metabolix was promoting these bioplastics as biobased and biodegradable, but functionally equivalent, alternatives to petroleum-based plastics.

The complaint alleges that during the Class Period, Metabolix, and certain controlling individuals of the Company, made fraudulent material misrepresentations and omissions regarding Metabolix's business and operations. Among other things, the complaint alleges that defendants materially misrepresented and/or failed to disclose the following adverse facts: (i) that the Telles joint venture would not meet its commercial phase benchmark as early as mid-2010, or even in 2011, which would allow the Metabolix to receive royalty payments and payments from services from Telles; (ii) that Mirel was not a commercially viable product that would offer value to Metabolix and its shareholders; and (iii) that, as a result of the foregoing, defendants lacked a reasonable basis for their positive statements about the Company and its prospects.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs